Impact of dexamethasone, etoposide, ifosfamide and carboplatin as concurrent chemoradiotherapy agents for nasal natural killer/T-cell lymphoma

Hatayama,Yoshiomi; Aoki,Masahiko; Kawaguchi,Hideo; Narita,Yuichiro; Hirose,Katsumi; Sato,Mariko; Takai,Yoshihiro

doi:10.3892/mco.2013.123

Impact of dexamethasone, etoposide, ifosfamide and carboplatin as concurrent chemoradiotherapy agents for nasal natural killer/T-cell lymphoma

Authors:
- Yoshiomi Hatayama
- Masahiko Aoki
- Hideo Kawaguchi
- Yuichiro Narita
- Katsumi Hirose
- Mariko Sato
- Yoshihiro Takai
View Affiliations

Affiliations: Department of Radiology, Hirosaki University School of Medicine, Hirosaki, Aomori 036-8562, Japan
Published online on: May 17, 2013 https://doi.org/10.3892/mco.2013.123
Pages: 680-684

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The nasal type of extranodal natural killer (NK)̸T‑cell lymphoma (NKTCL) is a rare aggressive lymphoma with poor prognosis. The reported 5-year overall survival for patients with localized nasal NKTCL treated with cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP) is <50%. Dexamethasone, etoposide, ifosfamide and carboplatin (DeVIC) chemotherapy was designed as a salvage chemotherapeutic regimen for aggressive lymphoma, comprising multidrug resistance (MDR) non-related agents and etoposide, which is considered to be effective against nasal NKTCL. An experimental chemoradiotherapy (CRT) is currently being designed using DeVIC as the concurrent chemotherapeutic regimen for nasal NKTCL. The aim of this study was to examine the initial outcome of this treatment and evaluate its effectiveness and feasibility. Six patients (age range, 29-82 years; median age, 68 years) were treated with CRT using DeVIC between April, 2004 and February, 2010. the median follow-up was 56 months (range, 11-80 months). All patients were administered 3‑6 cycles of full‑dose DeVIC regimen. The chemotherapy was administered concurrently with radiotherapy (RT) and was repeated every 3 weeks. RT was performed using 4-MV X-ray and the prescription dose was 46-50 Gy/23-25 fx (median, 50 Gy). After treatment, all patients were followed up at our hospital. A complete remission was achieved in 5 patients (83%) at 1 month after treatment. The 5-year overall survival and disease-free survival rates were 100%. No severe adverse effect (grade ≥3) was reported. In conclusion, the initial results of the experimental CRT with DeVIC for this type of aggressive lymphoma were very encouraging. Further investigation is required on concurrent CRT with 50 Gy/25 fx and 3 cycles of DeVIC comprising non-MDR agents and etoposide for nasal NKTCL.

View Figures

View References

1.	No authors listed:. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists Pathol Int. 50:696–702. 2000.PubMed/NCBI
2.	Chan JK, Quintanilla-Martinez L, Ferry JA, et al: Extranodal NK/T-cell lymphoma, nasal type. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, et al: IARC Press; Lyon: pp. 285–288. 2008
3.	Al-Hakeem DA, Fedele S, Carlos R and Porter S: Extranodal NK/T-cell lymphoma, nasal type. Oral Oncol. 43:4–14. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Suzuki R, Takeuchi K, Ohshima K and Nakamura S: Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 26:66–72. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Harabuchi Y, Yamanaka N, Kataura A, et al: Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. 335:128–130. 1990. View Article : Google Scholar : PubMed/NCBI
6.	Jaffe ES, Chan JK, Su IJ, et al: Report of the workshop on nasal and related extranodal angiocentric T/Natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 20:103–111. 1996. View Article : Google Scholar
7.	Jung CK, Lee KY, Kim Y, et al: Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas. Pathol Int. 51:355–363. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Yamaguchi M, Kita K, Miwa H, et al: Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 76:2351–2356. 1995. View Article : Google Scholar : PubMed/NCBI
9.	Drenou B, Lamy T, Amiot L, et al: CD3⁻CD56⁺non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance. Blood. 89:2966–2974. 1997.PubMed/NCBI
10.	Egashira M, Kawamata N, Sugimoto K, Kaneko T and Oshimi K: P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporine A and its analogue, PSC833. Blood. 93:599–606. 1999.PubMed/NCBI
11.	Kim GE, Cho JH, Yang WI, et al: Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 18:54–63. 2000.PubMed/NCBI
12.	Koom WS, Chung EJ, Yang WI, et al: Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 59:1127–1137. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Cheung MM, Chan JK, Lau WH, Ngan RK and Foo WW: Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 54:182–190. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Kim WS, Song SY, Ahn YC, et al: CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol. 12:349–352. 2001. View Article : Google Scholar : PubMed/NCBI
15.	Liang R, Todd D, Chan TK, et al: Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol. 13:666–670. 1995.PubMed/NCBI
16.	Ribrag V, Ell Hajj M, Janot F, et al: Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia. 15:1123–1126. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Shikama N, Ikeda H, Nakamura S, et al: Localized aggressive non-Hodgkin’s lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group. Int J Radiat Biol Phys. 51:1228–1233. 2001.
18.	Isobe K, Uno T, Tamaru J, et al: Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 106:609–615. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Yamaguchi M, Tobinai M, Oguchi M, et al: Phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: Final results of JCOG0211. J Clin Oncol. 27:5594–5600. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Yamaguchi M, Ogawa S, Nomoto Y, et al: Treatment outcome of nasal NK-cell lymphoma: a report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematopathol. 41:93–99. 2001. View Article : Google Scholar
21.	Sakata K, Fuwa N, Kodaira T, et al: Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol. 79:179–184. 2006. View Article : Google Scholar : PubMed/NCBI
22.	Kim SJ, Kim K, Kim BS, et al: Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 27:6027–6032. 2009. View Article : Google Scholar
23.	Li YX, Yao B, Jin J, et al: Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 24:181–189. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Wang B, Lu JJ, Ma X, et al: Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity. Leuk Lymphoma. 48:396–402. 2007. View Article : Google Scholar : PubMed/NCBI